Our institution is currently in a season of incredibly high scrutiny on BPAs (including non-provider BPAs and those that would be 100% actionable). I am curious if others are experiencing this same thing, and if so, have you developed specific criteria to meet in order to recommend a BPA and/or a flowsheet when assessing whether or not a BPA is the best way to incorporate a safety measure. We are an Epic institution.

Thanks!
Amanda Hurst, PharmD, BCPPS
Sanford Medical Center

Does anyone have experience with a Best Practice Advisory (BPA)/warning for Ketorolac use that is >5 days of therapy? What are the conditions for the BPA/warning to fire?